NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 109 filers reported holding NURIX THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,515,834 | -21.3% | 4,518,554 | -0.0% | 0.00% | 0.0% |
| Q2 2023 | $45,148,575 | +18.5% | 4,519,377 | +5.3% | 0.00% | 0.0% |
| Q1 2023 | $38,105,322 | -16.2% | 4,291,140 | +3.6% | 0.00% | 0.0% |
| Q4 2022 | $45,484,959 | -6.2% | 4,142,528 | +11.3% | 0.00% | -50.0% |
| Q3 2022 | $48,512,000 | +14.1% | 3,723,090 | +11.0% | 0.00% | +100.0% |
| Q2 2022 | $42,513,000 | +20.2% | 3,355,347 | +32.9% | 0.00% | 0.0% |
| Q1 2022 | $35,370,000 | -52.0% | 2,524,643 | -0.9% | 0.00% | -50.0% |
| Q4 2021 | $73,761,000 | -0.9% | 2,547,861 | +2.6% | 0.00% | 0.0% |
| Q3 2021 | $74,408,000 | +34.4% | 2,483,573 | +19.0% | 0.00% | 0.0% |
| Q2 2021 | $55,359,000 | -2.0% | 2,086,616 | +14.9% | 0.00% | 0.0% |
| Q1 2021 | $56,480,000 | +46.8% | 1,816,689 | +55.3% | 0.00% | +100.0% |
| Q4 2020 | $38,470,000 | +64.5% | 1,169,974 | +74.7% | 0.00% | 0.0% |
| Q3 2020 | $23,383,000 | – | 669,798 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |